The Moderna biotechnology company today announced that provisional data from their latest trials indicate that their Covid-19 vaccine is 94.5% effective in reducing the risk of contracting the disease.
In a statement, the company explained that during its third clinical trail which involved 30,000 , ninety-five cases of the disease were identified, of which only five had received the vaccine and 90 belonged to a group receiving a placebo injection. Eleven of the placebo test subjects were severely affected by the Covid virus.
According to Moderna, about 9% to 10% of vaccinated people experienced side effects after the second dose, such as fatigue, stiffness or redness around the injection site.
Following the release of the results, the executive director of Moderna said that “this is a crucial moment in the development of our vaccine against covid-19” and is the first clinical validation that our vaccine can protect against the virus.”
Based on provisional data relating to the safety and efficacy of the vaccine, the American company will submit an application for emergency use authorization in the coming weeks to the US Food and Drug Administration (FDA), the federal agency responsible for the control and supervision of the food and pharmaceutical sector, and also intends to apply for authorizations from international agencies.
By the end of the year, Moderna expects to have around 20 million doses of the mRNA-1273 vaccine available for distribution and maintains the goal of producing between 500 million and 1 billion doses in 2021.
The announcement comes a week after the pharmaceutical company Pfizer announced that according to provisional data based on trials of its vaccine an effectiveness rate of 90% was achieved.
The percentage effectiveness war has commenced!
Samantha Gannon
info at madeira-weekly.com
